
Volume 2 - Issue 2, Winter 2008 - Industry News: An Overview of the Latest Updates from Technology & Industry

Trials Show CRT Delays First Hospitalisation

Medtronic sponsored trials by REVERSE and PARTNERS HF have shown that cardiac resynchronisation therapy (CRT) delays the time to the first hospitalisation or death in patients with mild heart failure, and devices equipped with OptiVol® Fluid Status Monitoring identified patients who were at a significantly higher risk of having heart failure events in the near future. Although normally for patients with moderate or severe heart failure this research has shown that CRT has significant benefits for patients with mild heart failure, helping to prevent the progression of the condition. Similarly, the continuous device monitoring of heart failure patients in addition to periodic office visits can identify patients at increased risk of heart failure and allow for early intervention.

Published on : Sun, 21 Dec 2008